Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Tuberculosis | 68 | 2024 | 2029 | 5.930 |
Why?
|
Peru | 96 | 2025 | 894 | 4.010 |
Why?
|
Tuberculosis, Pulmonary | 33 | 2024 | 846 | 3.190 |
Why?
|
Mycobacterium tuberculosis | 35 | 2024 | 1931 | 2.430 |
Why?
|
Tuberculosis, Multidrug-Resistant | 25 | 2024 | 938 | 2.220 |
Why?
|
Antitubercular Agents | 31 | 2024 | 1390 | 1.990 |
Why?
|
Isoniazid | 8 | 2022 | 288 | 1.190 |
Why?
|
Sputum | 13 | 2024 | 511 | 0.920 |
Why?
|
Latent Tuberculosis | 7 | 2024 | 224 | 0.870 |
Why?
|
Contact Tracing | 12 | 2024 | 275 | 0.800 |
Why?
|
Family Characteristics | 12 | 2024 | 1001 | 0.770 |
Why?
|
Rifampin | 10 | 2023 | 345 | 0.740 |
Why?
|
Nitroimidazoles | 3 | 2022 | 118 | 0.520 |
Why?
|
HIV Infections | 16 | 2024 | 17492 | 0.460 |
Why?
|
Health Personnel | 8 | 2024 | 3384 | 0.420 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2017 | 4049 | 0.400 |
Why?
|
Adolescent | 56 | 2024 | 89163 | 0.370 |
Why?
|
Professional Competence | 1 | 2014 | 431 | 0.370 |
Why?
|
Mass Screening | 9 | 2024 | 5455 | 0.370 |
Why?
|
Prediabetic State | 3 | 2022 | 548 | 0.350 |
Why?
|
Medication Adherence | 5 | 2023 | 2190 | 0.320 |
Why?
|
Humans | 135 | 2025 | 768369 | 0.310 |
Why?
|
Genome, Bacterial | 3 | 2024 | 798 | 0.310 |
Why?
|
Mouth Mucosa | 2 | 2020 | 437 | 0.300 |
Why?
|
Antigens, CD1 | 2 | 2021 | 434 | 0.290 |
Why?
|
DNA, Bacterial | 4 | 2020 | 1474 | 0.290 |
Why?
|
Health Services Accessibility | 6 | 2024 | 5508 | 0.290 |
Why?
|
Young Adult | 40 | 2024 | 60038 | 0.280 |
Why?
|
Pyrazinamide | 2 | 2017 | 60 | 0.280 |
Why?
|
Child | 42 | 2024 | 80856 | 0.280 |
Why?
|
Child, Preschool | 28 | 2024 | 42620 | 0.270 |
Why?
|
Adult | 64 | 2025 | 223528 | 0.270 |
Why?
|
Infant | 27 | 2025 | 36496 | 0.270 |
Why?
|
BCG Vaccine | 4 | 2018 | 383 | 0.260 |
Why?
|
Lost to Follow-Up | 2 | 2024 | 123 | 0.250 |
Why?
|
Oxazoles | 3 | 2022 | 199 | 0.250 |
Why?
|
World Health Organization | 4 | 2024 | 1327 | 0.250 |
Why?
|
Delayed Diagnosis | 3 | 2024 | 469 | 0.250 |
Why?
|
Male | 73 | 2025 | 364761 | 0.240 |
Why?
|
Sensitivity and Specificity | 8 | 2024 | 14725 | 0.240 |
Why?
|
Quantitative Trait Loci | 2 | 2024 | 2126 | 0.240 |
Why?
|
Female | 77 | 2025 | 396926 | 0.240 |
Why?
|
Focus Groups | 4 | 2022 | 1448 | 0.230 |
Why?
|
Host-Pathogen Interactions | 2 | 2024 | 1462 | 0.230 |
Why?
|
Tuberculin Test | 6 | 2023 | 205 | 0.230 |
Why?
|
Bivalvia | 1 | 2023 | 55 | 0.230 |
Why?
|
Prevalence | 12 | 2024 | 15879 | 0.220 |
Why?
|
Breath Tests | 1 | 2024 | 300 | 0.210 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 1 | 2023 | 86 | 0.210 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2019 | 1898 | 0.190 |
Why?
|
Infant, Newborn | 15 | 2024 | 26394 | 0.190 |
Why?
|
Private Sector | 1 | 2024 | 395 | 0.180 |
Why?
|
Mother-Child Relations | 1 | 2025 | 501 | 0.180 |
Why?
|
Transportation | 1 | 2022 | 218 | 0.180 |
Why?
|
Cholesterol Ester Transfer Proteins | 1 | 2021 | 113 | 0.180 |
Why?
|
Microbial Sensitivity Tests | 7 | 2023 | 1965 | 0.180 |
Why?
|
Trehalose | 1 | 2021 | 88 | 0.180 |
Why?
|
Esters | 1 | 2021 | 212 | 0.180 |
Why?
|
Cough | 1 | 2024 | 598 | 0.180 |
Why?
|
Prisons | 1 | 2022 | 178 | 0.170 |
Why?
|
Middle Aged | 42 | 2024 | 223406 | 0.170 |
Why?
|
Sulfhydryl Compounds | 1 | 2021 | 298 | 0.170 |
Why?
|
Prisoners | 1 | 2023 | 317 | 0.170 |
Why?
|
Qualitative Research | 8 | 2023 | 3115 | 0.160 |
Why?
|
Radiography, Thoracic | 2 | 2024 | 1320 | 0.160 |
Why?
|
Parenting | 2 | 2025 | 707 | 0.160 |
Why?
|
HIV Long-Term Survivors | 1 | 2019 | 121 | 0.160 |
Why?
|
Gastric Juice | 1 | 2018 | 59 | 0.160 |
Why?
|
Antigens, CD1d | 1 | 2019 | 225 | 0.160 |
Why?
|
Amides | 1 | 2021 | 452 | 0.160 |
Why?
|
Drug Resistance, Multiple, Bacterial | 3 | 2018 | 590 | 0.160 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2023 | 4582 | 0.160 |
Why?
|
Prospective Studies | 21 | 2024 | 54913 | 0.160 |
Why?
|
Self Disclosure | 1 | 2019 | 249 | 0.150 |
Why?
|
Transients and Migrants | 1 | 2021 | 170 | 0.150 |
Why?
|
Vitamin E Deficiency | 1 | 2018 | 30 | 0.150 |
Why?
|
Antibiotics, Antitubercular | 1 | 2018 | 99 | 0.150 |
Why?
|
Immunoglobulin M | 1 | 2023 | 1528 | 0.150 |
Why?
|
Anti-HIV Agents | 2 | 2024 | 4563 | 0.150 |
Why?
|
Geologic Sediments | 1 | 2018 | 82 | 0.150 |
Why?
|
Specimen Handling | 2 | 2022 | 709 | 0.150 |
Why?
|
Tuberculosis Vaccines | 1 | 2017 | 48 | 0.140 |
Why?
|
National Health Programs | 2 | 2021 | 442 | 0.140 |
Why?
|
Suction | 1 | 2018 | 268 | 0.140 |
Why?
|
Directly Observed Therapy | 1 | 2018 | 139 | 0.140 |
Why?
|
Communicable Disease Control | 2 | 2021 | 857 | 0.140 |
Why?
|
Vitamin A Deficiency | 1 | 2017 | 88 | 0.140 |
Why?
|
Amino Acid Motifs | 1 | 2019 | 930 | 0.140 |
Why?
|
Health Facilities | 1 | 2022 | 576 | 0.140 |
Why?
|
Ethambutol | 1 | 2016 | 59 | 0.140 |
Why?
|
Linkage Disequilibrium | 1 | 2021 | 1998 | 0.130 |
Why?
|
Case-Control Studies | 8 | 2022 | 22286 | 0.130 |
Why?
|
Actigraphy | 1 | 2020 | 526 | 0.130 |
Why?
|
Comprehensive Health Care | 1 | 2017 | 123 | 0.130 |
Why?
|
Hypersensitivity, Immediate | 1 | 2019 | 350 | 0.130 |
Why?
|
Viral Load | 3 | 2023 | 3374 | 0.130 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 808 | 0.130 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2020 | 614 | 0.130 |
Why?
|
Amidohydrolases | 1 | 2016 | 160 | 0.130 |
Why?
|
Mothers | 3 | 2025 | 2210 | 0.130 |
Why?
|
Selection, Genetic | 1 | 2020 | 874 | 0.120 |
Why?
|
Caregivers | 3 | 2023 | 2302 | 0.120 |
Why?
|
Risk Factors | 19 | 2024 | 74915 | 0.120 |
Why?
|
Treatment Outcome | 18 | 2024 | 65408 | 0.120 |
Why?
|
Health Literacy | 1 | 2020 | 467 | 0.120 |
Why?
|
Cross-Sectional Studies | 10 | 2024 | 26348 | 0.120 |
Why?
|
Th17 Cells | 1 | 2021 | 798 | 0.120 |
Why?
|
Socioeconomic Factors | 4 | 2022 | 7863 | 0.120 |
Why?
|
Immunologic Memory | 1 | 2021 | 1371 | 0.120 |
Why?
|
Anticholesteremic Agents | 1 | 2021 | 972 | 0.120 |
Why?
|
Income | 1 | 2023 | 1878 | 0.110 |
Why?
|
Entamoebiasis | 1 | 2013 | 12 | 0.110 |
Why?
|
Protozoan Infections | 1 | 2013 | 38 | 0.110 |
Why?
|
Amebiasis | 1 | 2013 | 33 | 0.110 |
Why?
|
Giardiasis | 1 | 2013 | 28 | 0.110 |
Why?
|
Social Class | 1 | 2023 | 2000 | 0.110 |
Why?
|
Blastocystis Infections | 1 | 2013 | 17 | 0.110 |
Why?
|
Age Factors | 10 | 2021 | 18477 | 0.110 |
Why?
|
Body Height | 1 | 2020 | 1568 | 0.110 |
Why?
|
Bronchiectasis | 1 | 2015 | 139 | 0.110 |
Why?
|
Vitamin E | 1 | 2018 | 873 | 0.110 |
Why?
|
Social Stigma | 2 | 2023 | 785 | 0.110 |
Why?
|
Diabetes Mellitus | 4 | 2020 | 5887 | 0.110 |
Why?
|
Urban Population | 2 | 2020 | 2047 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1089 | 0.110 |
Why?
|
Molecular Epidemiology | 1 | 2015 | 473 | 0.110 |
Why?
|
Phylogeny | 1 | 2021 | 2841 | 0.110 |
Why?
|
Child Development | 1 | 2025 | 2328 | 0.100 |
Why?
|
Primary Prevention | 1 | 2020 | 1189 | 0.100 |
Why?
|
Dendritic Cells | 1 | 2024 | 2753 | 0.100 |
Why?
|
Diagnostic Tests, Routine | 1 | 2018 | 792 | 0.100 |
Why?
|
Feasibility Studies | 5 | 2025 | 5308 | 0.100 |
Why?
|
Drug Resistance, Bacterial | 2 | 2017 | 1061 | 0.100 |
Why?
|
Community Health Services | 1 | 2018 | 659 | 0.100 |
Why?
|
Macrophages | 2 | 2024 | 5797 | 0.100 |
Why?
|
Feces | 1 | 2019 | 1515 | 0.100 |
Why?
|
Breast Feeding | 1 | 2021 | 1365 | 0.100 |
Why?
|
Parents | 2 | 2017 | 3596 | 0.100 |
Why?
|
Disease Progression | 5 | 2021 | 13643 | 0.100 |
Why?
|
Cohort Studies | 11 | 2024 | 41782 | 0.100 |
Why?
|
Epidemics | 1 | 2017 | 517 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3210 | 0.090 |
Why?
|
Cost of Illness | 1 | 2021 | 1960 | 0.090 |
Why?
|
Hyperglycemia | 1 | 2020 | 1389 | 0.090 |
Why?
|
Nutritional Status | 2 | 2016 | 1623 | 0.090 |
Why?
|
Binding Sites | 1 | 2019 | 6029 | 0.090 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4570 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2020 | 2590 | 0.090 |
Why?
|
Medication Errors | 1 | 2017 | 783 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2024 | 16023 | 0.090 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2023 | 10358 | 0.090 |
Why?
|
Logistic Models | 6 | 2023 | 13323 | 0.090 |
Why?
|
Clinical Protocols | 3 | 2022 | 1444 | 0.090 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2015 | 3246 | 0.090 |
Why?
|
Weight Gain | 1 | 2020 | 2357 | 0.080 |
Why?
|
Vitamin D Deficiency | 1 | 2019 | 1389 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2021 | 2078 | 0.080 |
Why?
|
Incidence | 8 | 2020 | 21552 | 0.080 |
Why?
|
Sexual Behavior | 1 | 2019 | 2200 | 0.080 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2018 | 3793 | 0.080 |
Why?
|
Aged | 18 | 2024 | 171514 | 0.080 |
Why?
|
Blood Glucose | 2 | 2021 | 6429 | 0.080 |
Why?
|
Tobacco Smoke Pollution | 1 | 2014 | 828 | 0.080 |
Why?
|
Public Health | 1 | 2022 | 2693 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2020 | 2181 | 0.080 |
Why?
|
Adaptation, Psychological | 1 | 2019 | 2664 | 0.080 |
Why?
|
Cluster Analysis | 3 | 2021 | 2730 | 0.080 |
Why?
|
Nucleic Acid Amplification Techniques | 2 | 2023 | 333 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2021 | 10269 | 0.080 |
Why?
|
Health Behavior | 1 | 2019 | 2649 | 0.070 |
Why?
|
Interviews as Topic | 1 | 2015 | 2733 | 0.070 |
Why?
|
Feeding Behavior | 2 | 2017 | 3202 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 4 | 2024 | 3237 | 0.070 |
Why?
|
Bacterial Proteins | 1 | 2021 | 3861 | 0.070 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 7449 | 0.070 |
Why?
|
Emotions | 1 | 2019 | 2772 | 0.070 |
Why?
|
Triage | 2 | 2024 | 997 | 0.070 |
Why?
|
Glucose Tolerance Test | 2 | 2020 | 1181 | 0.070 |
Why?
|
Drug Therapy, Combination | 3 | 2023 | 6320 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 3 | 2024 | 18047 | 0.070 |
Why?
|
Genotype | 5 | 2019 | 13045 | 0.070 |
Why?
|
Patient-Centered Care | 3 | 2022 | 1439 | 0.070 |
Why?
|
Sex Factors | 4 | 2021 | 10647 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2022 | 3412 | 0.060 |
Why?
|
Multivariate Analysis | 5 | 2019 | 12096 | 0.060 |
Why?
|
Quality Improvement | 1 | 2021 | 3858 | 0.060 |
Why?
|
Social Support | 3 | 2022 | 2195 | 0.060 |
Why?
|
Vitamin D | 1 | 2019 | 3311 | 0.060 |
Why?
|
Lung | 2 | 2024 | 10090 | 0.060 |
Why?
|
Homosexuality, Male | 2 | 2024 | 1343 | 0.060 |
Why?
|
Area Under Curve | 2 | 2020 | 1640 | 0.060 |
Why?
|
Immunophenotyping | 2 | 2020 | 1868 | 0.060 |
Why?
|
Comorbidity | 2 | 2017 | 10601 | 0.060 |
Why?
|
Thioredoxin-Disulfide Reductase | 1 | 2024 | 52 | 0.060 |
Why?
|
Psychometrics | 1 | 2014 | 3072 | 0.060 |
Why?
|
Sleep | 1 | 2020 | 4796 | 0.060 |
Why?
|
Treatment Failure | 2 | 2023 | 2655 | 0.060 |
Why?
|
Clofazimine | 1 | 2023 | 41 | 0.060 |
Why?
|
Pilot Projects | 3 | 2022 | 8730 | 0.050 |
Why?
|
Exercise | 1 | 2020 | 5940 | 0.050 |
Why?
|
Longitudinal Studies | 4 | 2024 | 14766 | 0.050 |
Why?
|
Tuberculin | 1 | 2022 | 64 | 0.050 |
Why?
|
Odds Ratio | 3 | 2023 | 9687 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5367 | 0.050 |
Why?
|
Smoking | 2 | 2021 | 9099 | 0.050 |
Why?
|
Reverse Transcription | 1 | 2022 | 47 | 0.050 |
Why?
|
Public Sector | 1 | 2024 | 265 | 0.050 |
Why?
|
Body Mass Index | 2 | 2017 | 13030 | 0.050 |
Why?
|
Retrospective Studies | 6 | 2023 | 81835 | 0.050 |
Why?
|
Pandemics | 4 | 2022 | 8751 | 0.050 |
Why?
|
Electrolytes | 1 | 2022 | 278 | 0.050 |
Why?
|
Fluoroquinolones | 1 | 2023 | 309 | 0.050 |
Why?
|
Pregnancy | 5 | 2023 | 30179 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2021 | 2564 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2021 | 59679 | 0.050 |
Why?
|
Factor Analysis, Statistical | 1 | 2023 | 1007 | 0.040 |
Why?
|
Microfibrils | 1 | 2020 | 16 | 0.040 |
Why?
|
Weights and Measures | 1 | 2020 | 41 | 0.040 |
Why?
|
Indians, South American | 1 | 2020 | 34 | 0.040 |
Why?
|
Neck Pain | 1 | 2022 | 190 | 0.040 |
Why?
|
X-Rays | 1 | 2021 | 312 | 0.040 |
Why?
|
Internet | 1 | 2012 | 3123 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2022 | 39429 | 0.040 |
Why?
|
Mycolic Acids | 1 | 2020 | 54 | 0.040 |
Why?
|
Primary Health Care | 1 | 2017 | 4736 | 0.040 |
Why?
|
Regression Analysis | 2 | 2020 | 6353 | 0.040 |
Why?
|
Mutation | 3 | 2024 | 30235 | 0.040 |
Why?
|
Asthma | 1 | 2019 | 6274 | 0.040 |
Why?
|
Heredity | 1 | 2020 | 148 | 0.040 |
Why?
|
Hospitals, Public | 1 | 2021 | 205 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2023 | 876 | 0.040 |
Why?
|
Video Recording | 1 | 2025 | 974 | 0.040 |
Why?
|
Nasopharynx | 1 | 2022 | 420 | 0.040 |
Why?
|
Glycolipids | 1 | 2020 | 206 | 0.040 |
Why?
|
Lipids | 2 | 2021 | 3346 | 0.040 |
Why?
|
Administration, Oral | 2 | 2017 | 4040 | 0.040 |
Why?
|
Residence Characteristics | 2 | 2022 | 2119 | 0.040 |
Why?
|
Bacterial Typing Techniques | 1 | 2019 | 263 | 0.040 |
Why?
|
Genes, MDR | 1 | 2018 | 36 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2020 | 244 | 0.040 |
Why?
|
Self-Help Groups | 1 | 2019 | 193 | 0.040 |
Why?
|
Health Education | 1 | 2025 | 1059 | 0.040 |
Why?
|
Automation, Laboratory | 1 | 2018 | 102 | 0.040 |
Why?
|
Self Efficacy | 1 | 2022 | 651 | 0.040 |
Why?
|
Health Services | 1 | 2023 | 756 | 0.040 |
Why?
|
Developing Countries | 2 | 2024 | 2901 | 0.040 |
Why?
|
Condoms | 1 | 2019 | 338 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2021 | 589 | 0.040 |
Why?
|
Saliva | 1 | 2022 | 854 | 0.040 |
Why?
|
Antigen-Presenting Cells | 1 | 2021 | 964 | 0.040 |
Why?
|
Gender Identity | 1 | 2023 | 769 | 0.030 |
Why?
|
Hospitals, General | 1 | 2021 | 807 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9508 | 0.030 |
Why?
|
Skin Tests | 1 | 2019 | 639 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2019 | 4774 | 0.030 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 1 | 2019 | 478 | 0.030 |
Why?
|
Conserved Sequence | 1 | 2019 | 1163 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2020 | 20232 | 0.030 |
Why?
|
Genetic Variation | 2 | 2024 | 6607 | 0.030 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 252 | 0.030 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2019 | 822 | 0.030 |
Why?
|
Biological Evolution | 1 | 2021 | 1081 | 0.030 |
Why?
|
Spirometry | 1 | 2019 | 928 | 0.030 |
Why?
|
Urinalysis | 1 | 2018 | 369 | 0.030 |
Why?
|
Educational Status | 1 | 2023 | 2519 | 0.030 |
Why?
|
Pregnant Women | 1 | 2020 | 576 | 0.030 |
Why?
|
Gene Expression | 2 | 2019 | 7605 | 0.030 |
Why?
|
Gene Expression Regulation | 2 | 2024 | 11928 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2012 | 4877 | 0.030 |
Why?
|
Exercise Therapy | 1 | 2022 | 941 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2017 | 10784 | 0.030 |
Why?
|
Social Environment | 1 | 2019 | 1026 | 0.030 |
Why?
|
Protein Multimerization | 1 | 2019 | 979 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2019 | 1139 | 0.030 |
Why?
|
Entamoeba | 1 | 2013 | 5 | 0.030 |
Why?
|
Endolimax | 1 | 2013 | 6 | 0.030 |
Why?
|
Blastocystis hominis | 1 | 2013 | 6 | 0.030 |
Why?
|
Risk Assessment | 3 | 2020 | 24310 | 0.030 |
Why?
|
Vitamin A | 1 | 2017 | 611 | 0.030 |
Why?
|
Carotenoids | 1 | 2017 | 621 | 0.030 |
Why?
|
Giardia lamblia | 1 | 2013 | 23 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2019 | 3074 | 0.030 |
Why?
|
Antigen Presentation | 1 | 2019 | 1247 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 2018 | 443 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2016 | 637 | 0.030 |
Why?
|
Biological Assay | 1 | 2016 | 629 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2014 | 509 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2021 | 2359 | 0.030 |
Why?
|
Bacteriological Techniques | 1 | 2014 | 277 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3615 | 0.030 |
Why?
|
Diabetes Complications | 1 | 2019 | 1322 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2021 | 3164 | 0.030 |
Why?
|
Algorithms | 2 | 2023 | 14157 | 0.020 |
Why?
|
Patient Compliance | 1 | 2022 | 2696 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2019 | 1439 | 0.020 |
Why?
|
Overweight | 1 | 2023 | 2428 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2020 | 6242 | 0.020 |
Why?
|
Protein Conformation | 1 | 2019 | 3972 | 0.020 |
Why?
|
Self Report | 1 | 2023 | 3771 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2018 | 825 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 6995 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2016 | 1727 | 0.020 |
Why?
|
Computer Systems | 1 | 2012 | 470 | 0.020 |
Why?
|
Disease Transmission, Infectious | 1 | 2016 | 562 | 0.020 |
Why?
|
Adolescent Behavior | 1 | 2019 | 1192 | 0.020 |
Why?
|
Health Expenditures | 1 | 2023 | 2391 | 0.020 |
Why?
|
Counseling | 1 | 2019 | 1548 | 0.020 |
Why?
|
Family | 1 | 2021 | 3208 | 0.020 |
Why?
|
Information Systems | 1 | 2012 | 397 | 0.020 |
Why?
|
Geographic Information Systems | 1 | 2012 | 283 | 0.020 |
Why?
|
Genome-Wide Association Study | 2 | 2020 | 12771 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2018 | 15459 | 0.020 |
Why?
|
Genetic Loci | 1 | 2019 | 2630 | 0.020 |
Why?
|
Empathy | 1 | 2014 | 476 | 0.020 |
Why?
|
Monocytes | 1 | 2019 | 2589 | 0.020 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1792 | 0.020 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2018 | 952 | 0.020 |
Why?
|
Time Factors | 3 | 2017 | 40271 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4861 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2531 | 0.020 |
Why?
|
Housing | 1 | 2014 | 679 | 0.020 |
Why?
|
Models, Molecular | 1 | 2019 | 5441 | 0.020 |
Why?
|
Epidemiologic Studies | 1 | 2012 | 681 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6537 | 0.020 |
Why?
|
Health Policy | 1 | 2021 | 2699 | 0.020 |
Why?
|
Data Collection | 1 | 2017 | 3329 | 0.020 |
Why?
|
Pain Measurement | 1 | 2018 | 3577 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2021 | 3629 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 3271 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2013 | 2589 | 0.020 |
Why?
|
Protein Binding | 1 | 2019 | 9376 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10127 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3669 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4630 | 0.020 |
Why?
|
Program Development | 1 | 2012 | 1296 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2020 | 12561 | 0.020 |
Why?
|
Checklist | 1 | 2012 | 843 | 0.020 |
Why?
|
Risk | 1 | 2017 | 9642 | 0.020 |
Why?
|
Language | 1 | 2014 | 1557 | 0.020 |
Why?
|
Environmental Exposure | 1 | 2019 | 4533 | 0.010 |
Why?
|
Hospitalization | 1 | 2024 | 10845 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2016 | 4052 | 0.010 |
Why?
|
Depression | 1 | 2023 | 8235 | 0.010 |
Why?
|
Genomics | 1 | 2019 | 5912 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2019 | 4453 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2014 | 3590 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 6217 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8051 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 13065 | 0.010 |
Why?
|
Quality of Life | 1 | 2022 | 13497 | 0.010 |
Why?
|
Chronic Disease | 1 | 2015 | 9379 | 0.010 |
Why?
|
Diet | 1 | 2017 | 8098 | 0.010 |
Why?
|
Models, Statistical | 1 | 2014 | 5103 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15965 | 0.010 |
Why?
|
Mental Disorders | 1 | 2017 | 6879 | 0.010 |
Why?
|
HIV-1 | 1 | 2013 | 6909 | 0.010 |
Why?
|
Prognosis | 1 | 2016 | 30031 | 0.010 |
Why?
|
United States | 1 | 2023 | 73120 | 0.010 |
Why?
|
Animals | 1 | 2023 | 169424 | 0.010 |
Why?
|